Skip to Content

Coeptis Therapeutics Holdings Inc Ordinary Shares COEP

Morningstar Rating
$0.36 +0.02 (7.25%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

COEP is trading at a 68% discount.
Price
$0.34
Fair Value
$8.56
Uncertainty
Extreme
1-Star Price
$76.62
5-Star Price
$4.52
Economic Moat
Fwf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COEP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.33
Day Range
$0.320.38
52-Week Range
$0.292.19
Bid/Ask
$0.35 / $0.35
Market Cap
$12.81 Mil
Volume/Avg
88,989 / 280,128

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
7

Valuation

Metric
COEP
Price/Earnings (Normalized)
Price/Book Value
2.87
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
COEP
Quick Ratio
1.68
Current Ratio
1.76
Interest Coverage
−196.49
Quick Ratio
COEP

Profitability

Metric
COEP
Return on Assets (Normalized)
−258.49%
Return on Equity (Normalized)
−533.87%
Return on Invested Capital (Normalized)
−364.44%
Return on Assets
COEP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFtzlqbvvYdt$550.4 Bil
VRTX
Vertex Pharmaceuticals IncVzkxzklLwqmnb$101.7 Bil
REGN
Regeneron Pharmaceuticals IncKfhprlprKbrkxb$98.1 Bil
MRNA
Moderna IncBnfltytwnXchv$38.8 Bil
ARGX
argenx SE ADRCwvxwxcpkXzylr$21.7 Bil
BNTX
BioNTech SE ADRMdkyqywLwn$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncKgjrwdcNhtplqf$18.4 Bil
BMRN
Biomarin Pharmaceutical IncQdbfbnjkTjjdlm$17.1 Bil
RPRX
Royalty Pharma PLC Class AJgjlqmssZdtpml$12.5 Bil
INCY
Incyte CorpMfpwbrdqSyvmbj$11.9 Bil

Sponsor Center